SHANDONG KEYUAN PHARMACEUTICAL CO., LTD.

Shandong Keyuan Pharmaceutical Co., Ltd.

301281

CNE1000061V8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-06-13 pm EDT			5-day change	1st Jan Change
23.68 ^CNY	-0.29%		+2.82%	-30.43%

Apr. 21	Shandong Keyuan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 04	Certain A Shares of Shandong Keyuan Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	CI

Shandong Keyuan Pharmaceutical Co., Ltd. agreed to acquire 12% stake in NKD Pharma Co., Ltd. from a group of shareholders for CNY 180 million.

November 05, 2023

Shandong Keyuan Pharmaceutical Co., Ltd. (SZSE:301281) agreed to acquire 12% stake in NKD Pharma Co., Ltd. from a group of shareholders for CNY 180 million on November 3, 2023.

Latest news about Shandong Keyuan Pharmaceutical Co., Ltd.

Shandong Keyuan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 21	CI
Certain A Shares of Shandong Keyuan Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	Apr. 03	CI
Shandong Keyuan Pharmaceutical Co., Ltd. Proposes Cash Dividend for 2023	Mar. 28	CI
Shandong Keyuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Shandong Linuo Pharmaceutical Co., Ltd. announced that it expects to receive CNY 200 million in funding from Shandong Keyuan Pharmaceutical Co., Ltd.	Jan. 02	CI
Shandong Keyuan Pharmaceutical Co., Ltd. agreed to acquire 12% stake in NKD Pharma Co., Ltd. from a group of shareholders for CNY 180 million.	Nov. 05	CI
Shandong Keyuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Shandong Keyuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21	CI
Shandong Keyuan Pharmaceutical Co., Ltd. has completed an IPO in the amount of CNY 854.883 million.	23-03-30	CI
Shandong Keyuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-16	CI

Chart Shandong Keyuan Pharmaceutical Co., Ltd.

Duration

Period

Chart Shandong Keyuan Pharmaceutical Co., Ltd.

More charts

Shandong Keyuan Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development, production and sales of chemical APIs and their preparation products. The Company's main products include gliclazide, metformin hydrochloride, ropivacaine hydrochloride and others. The Company's products are used in hypoglycemic, anesthetic, cardiovascular and psychiatric diseases. The Company conducts its operations mainly in the domestic market.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHANDONG KEYUAN PHARMACEUTICAL CO., LTD.	-30.43%	353M
NOVO NORDISK A/S	+41.74%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+17.72%	246B
ROCHE HOLDING AG	+0.25%	225B
NOVARTIS AG	+10.42%	218B
AMGEN INC.	+3.68%	160B
PFIZER, INC.	-4.38%	156B